Foghorn Therapeutics Inc (FHTX)
$6.52
+0.27
(+4.32%)▲
Performance
- $6.22$6.74$6.52
4.6%
Downside
Day's Volatility :7.72%
Upside
3.26%
- $2.70$9.97$6.52
58.59%
Downside
52 Weeks Volatility :72.92%
Upside
34.6%
Returns
| Period | Foghorn Therapeutics Inc | |
|---|---|---|
3 Months | 18.76% | |
6 Months | 113.77% | |
1 Year | -22.01% | |
3 Years | -31.3% |
Highlights
Market Capitalization | 345.5M |
Book Value | - $2.29 |
Earnings Per Share (EPS) | -2.2 |
Wall Street Target Price | 13.75 |
Profit Margin | -274.23% |
Operating Margin TTM | -558.3% |
Return On Assets TTM | -20.46% |
Return On Equity TTM | -470.38% |
Revenue TTM | 33.9M |
Revenue Per Share TTM | 0.81 |
Quarterly Revenue Growth YOY | -4.9% |
Gross Profit TTM | -86.4M |
EBITDA | -99.4M |
Diluted Eps TTM | -2.2 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.16 |
EPS Estimate Next Year | -1.68 |
EPS Estimate Current Quarter | -0.63 |
EPS Estimate Next Quarter | -0.65 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 110.89%
Technicals Summary
Sell
Neutral
Buy
Foghorn Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Foghorn Therapeutics Inc | 18.12% | 113.77% | -22.01% | -31.3% | -64.02% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Foghorn Therapeutics Inc | NA | NA | NA | -2.16 | -4.7 | -0.2 | NA | -2.29 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Foghorn Therapeutics Inc | Buy | $345.5M | -64.02% | NA | -274.23% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Institutional Holdings
Flagship Ventures Management, Inc.
22.91%FMR Inc
4.86%Raymond James & Associates
4.03%Euclidean Capital LLC
2.84%BlackRock Inc
2.38%Vanguard Group Inc
1.99%
Company Information
foghorn therapeutics inc., a biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. the company uses its proprietary gene traffic control platform to identify, validate, and potentially drug targets within the system. it is developing fhd-286, a small-molecule enzymatic inhibitor of brg1 and brm for the treatment of acute myeloid leukemia and uveal melanoma; and fhd-609, a small molecule protein degrader of brd9 to treat patients with synovial sarcoma. the company is also developing preclinical and discovery programs, including selective brm targeting non-small-cell lung cancer; and selective arid1b modulators for bladder, ovarian, and endometrial cancer. it has a collaboration with merck sharp & dohme corp. to discover and develop novel oncology therapeutics against a transcription factor target. the company was founded in 2015 and is headquartered in cambridge, massachusetts.
Organization | Foghorn Therapeutics Inc |
Employees | 116 |
CEO | Mr. Adrian H. B. Gottschalk |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$6.52
+4.32%
Keyarch Acquisition Corp
$6.52
+4.32%
Connexa Sports Technologies Inc
$6.52
+4.32%
Us Value Etf
$6.52
+4.32%
First Wave Biopharma Inc
$6.52
+4.32%
Global X Msci Next Emerging
$6.52
+4.32%
Fat Projects Acquisition Corp
$6.52
+4.32%
Capital Link Global Fintech
$6.52
+4.32%
Applied Uv Inc
$6.52
+4.32%